Home › Astrocytoma › Texas
Pag-aaral pangklinika para sa Astrocytoma sa Texas
15 pag-aaral para sa Astrocytoma ang naghahanap ng mga kalahok sa mga site sa Texas.
Mga Lungsod sa Texas
Opisyal na teksto ng pag-aaral (English)
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
- M D Anderson Cancer Center, Houston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT03896568Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Baylor, Scott and White Research Institute, Dallas
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06047379A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Baylor Scott & White Research Institute, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), San Antonio
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT05765812Targeted Pediatric High-Grade Glioma Therapy
- Texas Children's Hospital, Houston
Nagre-recruitObservasyonal na pag-aaral
12 Months – 39 Years · Lahat ng kasarian · Na-update Set 8, 2026 · NCT05839379HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1
36 Months – 22 Years · Lahat ng kasarian · Na-update Set 4, 2026 · NCT03911388Study of Olutasidenib and Temozolomide in HGG
- Texas Children's Hospital, Houston
Nagre-recruitPhase 2
Edad 12 hanggang 39 · Lahat ng kasarian · Na-update Set 1, 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- University of Texas Health Mays Cancer Center, San Antonio
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT05303519Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Houston
- Research Site, San Antonio
Nagre-recruitPhase 1/2
Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT05417594Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
- Excel Diagnostics & Nuclear Oncology Center, Houston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT07733674Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
- M D Anderson Cancer Center, Houston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 16, 2026 · NCT04623931Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Texas Children's Hospital, Houston
Nagre-recruitMaagang Phase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Texas Children's Hospital, Houston
Nagre-recruitPhase 2
12 Months – 39 Years · Lahat ng kasarian · Na-update May 29, 2026 · NCT05843253HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- Houston Methodist Neurological Institute, Houston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 30, 2026 · NCT03596086HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
- Houston Methodist Neurological Institute, Houston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 30, 2026 · NCT03603405Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
- UT MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 25, 2025 · NCT05879367Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.